Moderna and BioNTech stocks experienced sharp volatility for a third day following a Phase 3 melanoma trial success involving Moderna's mRNA vaccine combined with Merck's Keytruda. Despite no new clinical data Friday, Moderna's shares surged 8%, continuing a pattern of large swings driven by investor repositioning around this single trial result. The full dataset is expected at the ESMO conference in late October, which could further influence the mRNA trade. This volatility is isolated within biotech stocks, not linked to broader market moves, and reflects high retail interest and speculative trading.
Merck's stock surged 73% over the past year, driven by a successful mRNA cancer vaccine trial with Moderna and FDA approval of new drugs like LIPFENDRA, an oral cholesterol treatment. The company has addressed concerns over the upcoming KEYTRUDA pate...
The iShares Genomics Immunology and Healthcare ETF (IDNA) surged 13.53% in one day, driven by positive Phase 3 trial results from Moderna and Merck. This jump came with 2.8 times average trading volume, reflecting strong investor interest. IDNA trade...
Virtus Biotech ETF (BBP) is recommended as a buy due to its focused investment in FDA-approved biotech companies and strong recent performance. The ETF uses an equal-weight, quarterly rebalancing strategy that captures gains from breakout stocks like...
Hedge funds have been steadily buying Pfizer shares, attracted by its 6.3% dividend yield and promising oncology drug pipeline. Despite challenges from upcoming patent expirations that could impact earnings, Pfizer's late-stage cancer treatments and ...
Moderna's stock surged 176.9% to $174.38 on August 19, 2026, boosting its market cap to about $69.6 billion. The company expects to end 2026 with $4.7-$5.2 billion in cash and investments, plus a $0.9 billion credit line. CEO Stéphane Bancel highligh...
